Effectiveness and Tolerability of Ofatumumab Versus First-line DMTs in Early RMS Patients: Phase 3b STHENOS Study Design

被引：0

作者：

Montalban, X. ^{[11
]}

Linker, R. ^{[1
]}

Centonze, D. ^{[2
,3
]}

Turner, B. ^{[4
]}

Sanchez-de la Rosa, R. ^{[5
]}

Nillos, L. ^{[6
]}

Ettle, B. ^{[7
]}

Raponi, E. ^{[8
]}

Thouvenot, E. ^{[9
,10
]}

机构：

[1] Univ Regensburg, Univ Str, Regensburg, Germany

[2] Univ Roma Tor Vergata, Dept Syst Med, Rome, Italy

[3] IRCCS Neuromed, Neurol Unit, Rome, Italy

[4] Royal London Hosp, Dept Neurol, London, England

[5] Novartis Pharma AG, Basel, Switzerland

[6] Novartis Corp Malaysia Sdn Bhd, Petaling Jaya, Selangor, Malaysia

[7] Novartis Pharma GmbH, Nurnberg, Germany

[8] Novartis Pharma SAS, Rueil Malmaison, France

[9] Univ Montpellier, CNRS, Inst Genom Fonct, INSERM, Montpellier, France

[10] Nimes Univ Hosp, Dept Neurol, Nimes, France

[11] Hosp Univ Vall Hebron, Ctr Esclerosi Multiple Catalunya Cemcat, Barcelona, Spain

来源：

EUROPEAN JOURNAL OF NEUROLOGY | 2021年 / 28卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

EPR-224

引用

页码：357 / 358

页数：2

共 50 条

[31] Safety and tolerability of conversion to siponimod with and without titration in patients with advancing forms of relapsing multiple sclerosis: interim results of the phase 3b EXCHANGE study
Bar-Or, A.
Weinstock-Guttman, B.
Mao-Draayer, Y.
Cruz, L. -A.
Meng, X.
Cox, G. M.
Cohan, S. L.
MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 574 - 575
[32] Symptom Impact of First-Line Dacomitinib versus Gefitinib in EGFR-Positive NSCLC: Results from a Randomized Phase 3 Study
Migliorino, M. R.
Mok, T.
Wu, Y.
Zhou, X.
Lee, K. H.
Nakagawa, K.
Niho, S.
Tsuji, F.
Linke, R.
Rosell, R.
Corral, J.
Pluzanski, A.
Sbar, E.
Sandin, R.
Reisman, A.
Wang, T.
White, J. L.
Cheng, Y.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2204 - S2205
[33] Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational study
Burmester, Gerd R.
Matucci-Cerinic, Marco
Mariette, Xavier
Navarro-Blasco, Francisco
Kary, Sonja
Unnebrink, Kristina
Kupper, Hartmut
ARTHRITIS RESEARCH & THERAPY, 2014, 16 (01)
[34] Bendamustine Versus Chlorambucil as First-Line Treatment in B Cell Chronic Lymphocytic Leukemia: An Updated Analysis from An International Phase III Study
Knauf, Wolfgang Ulrich
Lissitchkov, Toshko
Aldaoud, Ali
Liberati, Anna
Loscertales, Javier
Herbrecht, Roul
Juliusson, Gunnar
Postner, Gerhard
Gercheva, Liana
Goranov, Stefan
Becker, Martin
Hoeffken, Klaus
Huguet, Francoise
Foa, Robert
Merkle, Karlheinz
Montillo, Marco
BLOOD, 2008, 112 (11) : 728 - 728
[35] Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational study
Gerd R Burmester
Marco Matucci-Cerinic
Xavier Mariette
Francisco Navarro-Blasco
Sonja Kary
Kristina Unnebrink
Hartmut Kupper
Arthritis Research & Therapy, 16
[36] Tolerability and effectiveness of fulvestrant as first-line endocrine therapy in unselected patients with advanced breast cancer (ABC): Results of a multicenter, single arm, non-interventional study
Zhao, Yannan
Geng, Cuizhi
Zhang, Hongwei
Cai, Li
Yao, Herui
Lin, Ying
Liu, Jianxia
Yang, Jin
Zhang, Jin
Wang, Xiaojia
Li, Yafen
Pang, Danmei
Sun, Tao
Wang, Xi
Ma, Jie
Zang, Aimin
Xu, Zhengyang
Wang, Yongsheng
Wang, Chuan
Hu, Xichun
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[37] Trial design for a phase 3 study evaluating pemigatinib (INCB054828) versus gemcitabine plus cisplatin chemotherapy in first-line treatment of patients with cholangiocarcinoma with FGFR2 rearrangement.
Bekaii-Saab, Tanios S.
Valle, Juan W.
Borad, Mitesh J.
Melisi, Davide
Vogel, Arndt
Feliz, Luis
Lihou, Christine Francis
Zhen, Huiling
Abou-Alfa, Ghassan K.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
[38] Clinical effectiveness and cost-effectiveness of first-line early combination of dipeptidyl peptidase 4 inhibitors and metformin in patients with type 2 diabetes in Taiwan: A modelling study
Nguyen, Thi Thuy Dung
Chen, Hsuan-Ming
Lin, Hung-Wei
Ou, Huang-Tz
Wang, Chih-Yuan
DIABETES OBESITY & METABOLISM, 2025, 27 (04): : 2183 - 2192
[39] Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial
Sagara, Issaka
Beavogui, Abdoul Habib
Zongo, Issaka
Soulama, Issiaka
Borghini-Fuhrer, Isabelle
Fofana, Bakary
Traore, Aliou
Diallo, Nouhoum
Diakite, Hamadoun
Togo, Amadou H.
Koumare, Sekou
Keita, Mohamed
Camara, Daouda
Some, Anyirekun F.
Coulibaly, Aboubacar S.
Traore, Oumar B.
Dama, Souleymane
Goita, Siaka
Djimde, Moussa
Bamadio, Amadou
Dara, Niawanlou
Maiga, Hamma
Sidibe, Bouran
Dao, Francois
Coulibaly, Moctar
Alhousseini, Mohamed Laraine
Niangaly, Hamidou
Sangare, Boubou
Diarra, Modibo
Coumare, Samba
Kabore, Moise J. T.
Ouattara, San Maurice
Barry, Aissata
Kargougou, Desire
Diarra, Amidou
Henry, Noelie
Sore, Harouna
Bougouma, Edith C.
Thera, Ismaila
Compaore, Yves D.
Sutherland, Colin J.
Sylla, Malick Minkael
Nikiema, Frederic
Diallo, Mamadou Saliou
Dicko, Alassane
Picot, Stephane
Borrmann, Steffen
Duparc, Stephan
Miller, Robert M.
Doumbo, Ogobara K.
LANCET, 2018, 391 (10128): : 1378 - 1390
[40] Cryoballoon catheter ablation versus antiarrhythmic drugs as a first-line therapy for patients with paroxysmal atrial fibrillation: Rationale and design of the international Cryo-FIRST study
Hermida, Jean Sylvain
Chen, Jian
Meyer, Christian
Iacopino, Saverio
Arena, Giuseppe
Pavlovic, Nikola
Velagic, Vedran
Healey, Stewart
Packer, Douglas L.
Pitschner, Heinz-Friedrich
de Asmundis, Carlo
Kuniss, Malte
Chierchia, Gian Battista
AMERICAN HEART JOURNAL, 2020, 222 : 64 - 72

← 1 2 3 4 5 →